Skip to NavigationSkip to content

Cost of over 350 drugs expected to increase in 2023

Published on 03/01/23 at 11:40am

With many pharma companies preparing for President Joe Biden’s Inflation Reduction Act (IRA) to begin having an impact, and inflation continuing to soar, the cost of at least 350 drugs are expected to rise in the US throughout 2023.

Pfizer, AstraZeneca, GlaxoSmithKline (GSK), Bristol Myers Squibb and Sanofi, among others, are some of the drugmakers who are expected to raise the prices of their products from January this year.

As well as Biden’s IRA, the upcoming price increases are also in response to the ongoing cost of living crisis and continuing supply chain issues which have led to higher manufacturing costs for many medicines.

Following the IRA, the government’s Medicare programme will be able to negotiate drug prices for drugs without competition from 2026. The drugs that have been selected for the 2026 price negotiations will be announced in September 2023.

Antonio Ciaccia, President of 3 Axis Advisors, told Reuters that “Drugmakers have to take a harder look at calibrating those launch prices out of the gate… so they don’t box themselves in into the point where in the future, they can’t price increase their way back into profitability.”

 

Betsy Goodfellow


Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches